Safety, Efficacy, and Pharmacokinetics of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies BMS-986414 (C135-LS) and BMS-986413 (C144-LS) Administered Subcutaneously in Non-Hospitalized Persons with COVID-19 in a Phase 2 Trial

By sjmartinez • May 15, 2024

Corado KC, Chew KW, Giganti MJ, Mu Y, Fletcher CV, Currier JS, Daar ES, Wohl DA, Li JZ, Moser CB, Ritz J, Javan AC, Neytman G, Caskey M, Hughes MD, Smith DM, Eron JJ; ACTIV-2/A5401 Study Team. Safety, Efficacy, and Pharmacokinetics of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies BMS-986414 (C135-LS) and BMS-986413 (C144-LS) Administered Subcutaneously in Non-Hospitalized Persons with COVID-19 in a Phase 2 Trial. Pathog Immun. 2024 May 6;9(1):138-155. doi: 10.20411/pai.v9i1.660. PMID: 38746756; PMCID: PMC11093219.

Tags: covid-19, Harbor UCLA, Infectious Diseases, Monoclonal antibodies, outpatient treatment, Publications, SARS-CoV-2, subcutaneous

Single-cell analyses identify monocyte gene expression profiles that influence HIV-1 reservoir size in acutely treated cohorts

Ehrenberg PK, Geretz A, Volcic M, Izumi T, Yum LK, Waickman A, Shangguan S, Paquin-Proulx D, Creegan M, Bose M, Machmach K, McGraw A, Narahari[...]

Differences in fat distribution between metabolically unhealthy people with normal weight versus obesity, NHANES 2011-2018

Anand S, Pasupneti T, Pak Y, Kalangi ST, Garg R. Differences in fat distribution between metabolically unhealthy people with normal weight versus obesity, NHANES 2011-2018.[...]

Methylation risk score of C-reactive protein associates sleep health with related health outcomes

Wang Z, Wallace DA, Spitzer BW, Huang T, Taylor KD, Rotter JI, Rich SS, Liu PY, Daviglus ML, Hou L, Ramos AR, Kaur S, Durda[...]